Tau Protein News and Research

RSS

Tau proteins are microtubule-associated proteins found in neurons in the brain.

Diabetes may be linked to buildup of brain tangles associated with Alzheimer’s disease

Diabetes may be linked to the buildup of tangles or tau in the brain, separate from Alzheimer's disease, according to a new study published in the September 2, 2015, online version of Neurology, the medical journal of the American Academy of Neurology.

3 Sep 2015

MetLife Foundation Awards for Medical Research presented at AAIC 2015

At the Alzheimer's Association International Conference 2015 in Washington D.C., MetLife Foundation presented its annual MetLife Foundation Awards for Medical Research. These awards were presented to Randall Bateman, M.D., and Christian Haass, Ph.D., for their contributions in advancing Alzheimer's disease research.

21 Jul 2015

C2N-8E12 (ABBV-8E12) gets orphan drug designation from FDA for PSP treatment

C2N Diagnostics and AbbVie today announced that the U.S. Food and Drug Administration has granted their investigational recombinant humanized anti-tau antibody, C2N-8E12 (ABBV-8E12), an orphan drug designation for the treatment of progressive supranuclear palsy (PSP).

17 Jul 2015

New research offers potential for early intervention to prevent neurodegenerative diseases

New research led by investigators at Beth Israel Deaconess Medical Center provides the first direct evidence linking traumatic brain injury to Alzheimer's disease and chronic traumatic encephalopathy (CTE) -- and offers the potential for early intervention to prevent the development of these debilitating neurodegenerative diseases.

16 Jul 2015

Hartmuth Kolb named recipient of 2015 Alzheimer Award

The Journal of Alzheimer's Disease is proud to announce that Hartmuth Kolb, PhD, Head of Neuroscience Biomarkers, Johnson & Johnson, San Diego, CA, has been chosen as the recipient of the 2015 Alzheimer Award presented by the Journal of Alzheimer's Disease in recognition of his outstanding work on the importance and imaging of neurofibrillary tangles (NFTs) and Alzheimer's disease (AD).

26 Jun 2015

New in vitro system could become important tool in search for potential drugs against Alzheimer’s

A typical characteristic of the brain of an Alzheimer sufferer is the presence of insoluble Tau protein aggregates. Scientists at VIB, KU Leuven and Janssen Pharmaceutica have demonstrated that the distribution of these aggregates through the brain is facilitated by synaptic connections between brain cells.

26 May 2015

Ground-breaking study characterizes early-stage Alzheimer's abnormalities in the intact brain

Alzheimer's disease (AD) is a neurodegenerative condition that strikes at the heart of what makes us human: the ability to think, to feel, to remember and to communicate with those around us. The tragedy is compounded by the fact that there is currently no cure, no treatment, and no diagnostic method capable of identifying Alzheimer's at its early stages.

6 May 2015

Immunotherapy reverses memory problems in animal model of Alzheimer's disease

A new study from the University of Texas Medical Branch at Galveston has revealed that a single dose of an immunotherapy reverses memory problems in an animal model of Alzheimer's disease. The article appears in the March 25 issue of the Journal of Neuroscience.

26 Mar 2015

UCLA-led team validates first standardized protocol for tracking early signs of Alzheimer's disease

After six years of painstaking research, a UCLA-led team has validated the first standardized protocol for measuring one of the earliest signs of Alzheimer's disease -- the atrophy of the part of the brain known as the hippocampus.

26 Mar 2015

Study: Progression of dysfunctional tau protein drives cognitive decline in Alzheimer's disease

By examining more than 3,600 postmortem brains, researchers at Mayo Clinic's campuses in Jacksonville, Florida, and Rochester, Minnesota, have found that the progression of dysfunctional tau protein drives the cognitive decline and memory loss seen in Alzheimer's disease.

24 Mar 2015

AbbVie signs exclusive worldwide license agreement with C2N for Alzheimer's disease therapies

AbbVie today announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders.

19 Mar 2015

Intrinsically disordered proteins have ability to alter their configuration

Like the shape-shifting robots of "Transformers" fame, a unique class of proteins in the human body also has the ability to alter their configuration. These so-named intrinsically disordered proteins (IDPs) lack a fixed or ordered three-dimensional structure, which can be influenced by exposure to various chemicals and cellular modifications.

26 Feb 2015

New skin test may help detect abnormal proteins in patients with Alzheimer's and Parkinson's diseases

Scientists have discovered a skin test that may shed new light on Alzheimer's and Parkinson's diseases, according to a study released today will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, D.C., April 18 to 25, 2015.

25 Feb 2015

Scientists identify role of tau-associated MAPT gene in development of Alzheimer's disease

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, has identified the microtubule-associated protein tau (MAPT) gene as increasing the risk for developing Alzheimer's disease (AD).

18 Feb 2015

UAB research suggests potential therapeutic target for patients with frontotemporal dementia

Drugs that boost the function of a specific type of neurotransmitter receptor may provide benefit to patients with the second most common type of dementia, according to research by scientists at the University of Alabama at Birmingham published today in the Journal of Neuroscience.

4 Dec 2014

Blocking key brain receptor cell could neutralize biological consequences of Alzheimer's

Blocking a key receptor in brain cells that is used by oxygen free radicals could play a major role in neutralizing the biological consequences of Alzheimer's disease, according to researchers at Temple University.

19 Nov 2014

Multi-institutional study establishes new criteria for Alzheimer's-related memory disorder

A multi-institutional study has defined and established criteria for a new neurological disease closely resembling Alzheimer's disease called primary age-related tauopathy (PART).

14 Nov 2014

Study defines, establishes criteria for primary age-related tauopathy

A multi-institutional study has defined and established criteria for a new neurological disease closely resembling Alzheimer's disease called primary age-related tauopathy (PART). Patients with PART develop cognitive impairment that can be indistinguishable from Alzheimer's disease, but they lack amyloid plaques. Awareness of this neurological disease will help doctors diagnose and develop more effective treatments for patients with different types of memory impairment.

13 Nov 2014

New culture system confirms amyloid theory, can revolutionize drug discovery for Alzheimer's disease

An innovative laboratory culture system has succeeded, for the first time, in reproducing the full course of events underlying the development of Alzheimer's disease.

13 Oct 2014

TauRx achieves target enrolment in second LMTX Phase III clinical trial for Alzheimer's disease

TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer's disease into the second of its two Phase III clinical trials of LMTX, a tau aggregation inhibitor, for the treatment of Alzheimer's disease.

22 Sep 2014